Bioactive RNAs are getting closer to real-world products

Oct 13

Kresko is moving beyond lab scale toward first production runs, clearer product definitions, and pilot and co-development opportunities with potential customers.

🧪 From lab scale to product readiness

With scale-up work advancing in both the U.S. and Europe, Q4 is focused on generating first pilot samples, refining the production process, and aligning regulatory requirements with product development.

🤝 Market pull is helping shape the roadmap

Commercial conversations are becoming more concrete, with potential customers increasingly pushing toward first pilot projects and co-development. That progress is also reflected in new LOIs with strategic global partners, helping us refine the product roadmap around real market needs.

🔬 The science keeps moving forward

While Kresko is increasingly focused on go-to-market execution, our scientific work continues to evolve.

In the U.S., we are expanding our scientific network through a collaboration with researchers at MIT. In Europe, we are advancing a collaboration with a research group at the University of the Basque Country (UPV/EHU) to evaluate bioactive RNAs in ex vivo human intestinal biopsies.

And we haven’t forgotten about Serkanto-AI. Kresko was selected for the Google for Startups Cloud Program, adding infrastructure, technical support, and cloud resources to accelerate our RNA discovery platform.

🌍 Global momentum keeps building

Kresko continues building across regions.

In Asia, we presented at SPACE-F Demo Day in Bangkok. In Latin America, we participated in the Volcano Summit in Guatemala and our CSO took part in the BCR Agtech Forum 2026.

Momentum in Europe is also building. Kresko was selected for equity-free support in Europe, helping lay the foundations for pilot execution closer to potential customers in the region.

Different geographies, same signal: bioactive RNAs are attracting growing attention.

What comes next

The direction is clear: move scale-up forward, validate closer to humans, build with customers, and turn bioactive RNAs into a commercially relevant ingredient category.

Q4 will be an important execution quarter for Kresko — and we’re excited about what comes next.